January 11, 2001
SAN FRANCISCO, Jan. 10 /PRNewswire/ via NewsEdge Corporation -
Acorda Therapeutics will be presenting at the J.P. Morgan H&Q Healthcare Conference in San Francisco on Wednesday, January 10, 2001 at 2:30 p.m. PST.
This presentation will be webcast live and can be accessed through the J.P. Morgan H&Q website, at http://www.chasehq.com/events/index.html. The presentation will be available on Acorda's corporate site, located at http://www.acorda.com, within 24 hours of the presentation.
Ron Cohen, M.D., President and CEO of Acorda, will provide an overview of the company and discuss corporate goals for 2001.
Acorda Therapeutics is a privately held biotechnology company developing therapies for individuals with spinal cord injury (SCI), multiple sclerosis (MS), and other central nervous systems disorders. The Company's lead product, Fampridine-SR, is in late Phase 2 clinical trials for chronic spinal cord injury, and for multiple sclerosis. Fampridine-SR restores the ability of damaged nerves to conduct electrical impulses, and is the only drug in clinical trials for individuals with chronic, or long term, SCI.
The Company's human monoclonal antibody, M1, has been shown to remyelinate the central nervous system in animal models, and is in preclinical development for MS. Acorda is also developing protein- and stem cell-based technologies to regenerate and repair the spinal cord and brain.
SOURCE Acorda Therapeutics
CONTACT: Tierney Saccavino of Acorda Therapeutics, 914-347-4300 ext. 104, e-mail firstname.lastname@example.org